-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Aynk2QXpNzGSKjpVi9AgLjyPAvaJYH3XQdol7atfcoPf1xGyzf3Hw8pDFHQP9jS/ ZCIfAzXkwn5wRpMNjSS6/Q== 0001203944-06-000016.txt : 20061107 0001203944-06-000016.hdr.sgml : 20061107 20061107130924 ACCESSION NUMBER: 0001203944-06-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20061106 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061107 DATE AS OF CHANGE: 20061107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RAPTOR PHARMACEUTICALS CORP. CENTRAL INDEX KEY: 0001203944 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980379350 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50720 FILM NUMBER: 061193030 BUSINESS ADDRESS: STREET 1: 9 COMMERCIAL BLVD, SUITE 200 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-382-1390 MAIL ADDRESS: STREET 1: 9 COMMERCIAL BLVD, SUITE 200 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: HIGHLAND CLAN CREATIONS CORP. DATE OF NAME CHANGE: 20060531 FORMER COMPANY: FORMER CONFORMED NAME: HIGHLAND CLAN CREATIONS CORP DATE OF NAME CHANGE: 20021106 8-K 1 form8k110606.htm RAPTOR PR WASHINGTON UNIV 110606

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 6, 2006

 

RAPTOR PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

 

Delaware

000-50720

98-0379350

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

9 Commercial Blvd., Suite 200, Novato, California 94949

(Address of principal executive offices and Zip Code)

 

Registrant’s telephone number, including area code: (415) 382-8111

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

- 2 -

 

 

 

Item 8.01 Other Events

 

On November 6, 2006, the Company issued a press release regarding its wholly-owned subsidiary, Raptor Pharmaceutical Inc.’s, exclusive worldwide license for Mesd reagents for the treatment of cancer and osteoporosis with Washington University, St. Louis and the appointment by Raptor Pharmaceutical Inc. of Dr. Andres Lozano to its Medical and Scientific Advisory Board. The Company’s press release issued on November 6, 2006 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

 

Exhibits

 

 

99.1

  

Press release of the Company dated November 6, 2006 regarding Raptor Pharmaceutical Inc.’s,

 

 

exclusive worldwide license for Mesd reagents for the treatment of cancer and osteoporosis

 

 

with Washington University, St. Louis and the appointment of Dr. Andres Lozano to

 

 

Raptor Pharmaceutical Inc.’s Medical and Scientific Advisory Board.

           

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 


 

 

 

RAPTOR PHARMACEUTICALS CORP.

 

 


By: /s/ Kim R. Tsuchimoto

 

 

 

Kim R. Tsuchimoto
Chief Financial Officer, Treasurer and Secretary
Date: November 7, 2006

 

 

 

 

 

 

 

 EX-99 2 raptorpressrelease110606.htm RAPTOR PRESS RELEASE 110606

 

Exhibit 99.1

 

NEWS

 

 

Contacts:

 

Kim R. Tsuchimoto 

CFO, Treasurer and Secretary

Raptor Pharmaceutical Inc. 

(415) 382-1390

info@raptorpharma.com

 

 

Raptor Pharmaceuticals Corp. Announces an

Exclusive Worldwide License Agreement

for Mesd Reagents for

Treatment of Cancer and Osteoporosis

 

Novato, California, November 6, 2006 – Raptor Pharmaceuticals Corp. (the “Company”) (OTC Bulletin Board: RPTP.OB), today announced that effective November 2, 2006 its wholly-owned subsidiary, Raptor Pharmaceutical Inc., signed an exclusive worldwide license agreement for the use of Mesd reagents for therapeutic treatment of cancer and osteoporosis with Washington University, St. Louis. Mesd is a chaperone protein necessary for the proper folding of the signal transduction receptors LRP5 and LRP6.

 

Dr. Christopher Starr, the Company’s Chief Executive Officer explained “Mesd significantly adds to our growing franchise in the drug targeting area. Similar to our RAP molecule, Mesd is a natural human receptor chaperone protein that has the potential to act as both a receptor targeting therapeutic, as well as a targeted delivery platform that could be used to deliver other drugs. Mesd complements and extends our current programs and we believe will increase our reach and capabilities into a number of under-served disease indications with substantial market potential.”

 

Dr. Todd Zankel, the Company’s Chief Scientific Officer, stated “Raptor intends to initially test the potential of Washington University’s Mesd-based peptides for the treatment of cancer and osteoporosis. Mesd-based peptides may be useful in the therapeutic regulation of LRP5 and LRP6 in vivo. LRP5 has recently shown to be a critical modulator of bone density, while Dr. Guojun Bu’s lab at Washington University has demonstrated that LRP6 is an oncoprotein. We are pleased to have the opportunity to work with Dr. Bu, an Associate Professor in the Department of Pediatrics and the Department of Cell Biology and Physiology, who has been making significant progress on Mesd for the past three years. We are looking forward to a development effort designed to realize the full potential of this program including the lead drug product candidates developed to date by Dr. Bu and his staff.”

 

New Scientific Advisor

 

The Company also announced the appointment of Andres Lozano, M.D., Ph.D., to its Medical and Scientific Advisory Board. Dr. Lozano earned his M.D. from the University of Ottawa and his Ph.D. in Neurobiology from McGill University, Montreal. He was appointed to the neurosurgical faculty at the

 

 


 

 

 

University of Toronto in 1991 and became full Professor in 1999. Dr. Lozano is currently a Professor and holds the RR Tasker Chair in Functional Neurosurgery and a Canada Research Chair in Neuroscience at the University of Toronto. He also serves as Head of Applied and Interventional Research at the Toronto Western Research Institute.

 

Dr. Lozano’s research is focused on understanding the cellular pathogenesis of and developing novel treatments for neurological disorders including Parkinson’s disease and dystonia (abnormal muscle contractions.) His work has appeared in over 200 publications and he has been an invited lecturer or visiting professor throughout the world. Dr. Lozano serves on the boards and executive teams of several international organizations including the World Society for Stereotactic and Functional Neurosurgery where he currently serves as President.

 

“Dr. Lozano is a great addition to our Medical and Scientific Advisory Board. His expertise in research and clinical testing in patients with neurodegenerative diseases will complement Raptor’s efforts towards the Company’s brain delivery development program and the Company’s potential treatment of brain disorders,” said Dr. Todd Zankel.

About Raptor

Raptor Pharmaceuticals Corp. owns 100% of Raptor Pharmaceutical Inc., an early stage biotechnology research and development company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins.

About Washington University

Washington University is a leader in scientific research and ranks 5th among all educational institutions receiving research support from the National Institutes of Health.

 

  

FORWARD LOOKING STATEMENTS

 

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the Company’s future results of operation or future financial performance, including, but not limited to statements with respect to the Company’s ability to develop and commercialize Mesd reagents for the treatment of cancer and osteoporosis, Mesd’s ability to act as a receptor-targeting therapeutic or targeted delivery platform, and the effect of Dr. Lozano’s appointment to the Company’s Medical and Scientific Advisory Board on the Company’s brain delivery development efforts and brain disorder treatment development efforts. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company’s forward looking statements from fruition include that the Company’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that the Company is unable to retain or attract key employees whose knowledge is essential to its research and development efforts; that unforeseen scientific difficulties develop with the Company’s processes; that the Company’s patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that the Company’s research and development efforts may not lead to the development of any drug products; that the Company’s products, if developed, may not work as well as hoped or worse, that the Company’s products may harm recipients; and that the Company may not be able to raise sufficient funds for development or working capital when it requires it. As well, the Company’s products, if developed, may not be approved for sale to the public. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company’s filings from time to time with the Securities and Exchange Commission (“SEC”), which the Company strongly urges you to read and consider, including the Company’s Registration Statement on Form SB-2 that was declared effective on July 10, 2006, and the Company’s quarterly report on Form 10-QSB filed with the SEC on July 17, 2006, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements set forth in the Company’s reports filed with the SEC. The Company expressly disclaims any intent or obligation to update any forward-looking statements.

 

 

 

 

 

 

 

 

 

 GRAPHIC 3 img1.gif GRAPHIC begin 644 img1.gif M1TE&.#EAU0!'`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'_ M"TU33T9&24-%.2XP%P````MM0+-.6A0JZ$_A2*-V2J+ M"P(N7"WMJ73JRJ8#4`S(3V(A0#9JV)M@SX[$ZF*`E*YJ8Z:-^W%L M6:ET7!0NP:)9C![LZZHHEJ*M^BY4[!>;5,"#^+A2K+!OE@%M`V-CO/#Q MH,"'!TU^V%@@X=(R]QX<5';`H(&#G@Z8C9=@4]D$!N3>[4*TPCZZ"4BI/4@* M6=W(H;Y&R!H%`>=/H3^?3F#Y:KO)D;O`@GI@X3*;M5A,PAFYI&%7GGF.4>6BE`%YX)XJ[48%7VMK>BB M>2Z4-F)K**"07XOF63=0*T\!"16.*;J%'D%V$9"%5&/IYB-F2Z9&$7MMH9`% MA0K"B,TU6&+6VV&!24'@%*AA*":-)+K@@E.7$2B%D"+:-^6`=Q*`BFW-X?+'9UV(?56+CYG_88-BB5@ILF%.'MI5%0!]-OED4G=B8*9A!K8P5W5:K9055 MD6[ZYAT63Q4Y`'<$T=+*9*<4_ZE<8J\FAAYKDKZYFG'F,6B0<6T=%MVH;@[W M:$5^VF=60J8BQ%96%A84&X3;,4L@IJ;%N=6$`AUJ'[;9XD=`E2YDN%U[FD6S M&8<4M0*B5@1@L1&11_9F$&M/*0"5O+])=QY"E18Z4!\U@NN=%,'%:Q`6-Y(U MB#1#0>H=M=%J5)^O?V4H9D.HXH?MLP8ZJVVU#$W[;4'>MF?P5^U*:F)'(ZK( M[U^B.MP0C2UN>5#`S%*W+$.D8GQAO?$*?"Q%U'ID,JC2WA?R8B,J6^6SK`*< MX+8.18TH0>6V%^)2$@<(HL)73M:*48-X6M:]0.KR0!FWOHU'&]KCB=CVQ#UP=I:G]=$,^KI0I5Z`25IZ*0K<^,5-@"!>[0V<S/>B;X9VZ><5"X3OHKL8D8IMT5E=UMJ7IO4UR&YD2=]"8B.C$R5,BF`#G`L7`IR3*600&GM2 M\3+SNS)":S#:FN'KG$8[;)21+$V$GFOJ:*7K?6YS31K78C*8NK+0#F=/`9<( M1Y@B_C`$9S9+823#B+0Q\F5D>)-A8Y9&LH5TS(P%R=\/0ZDMJ'#L/FA"&1$' MLYG)N`H;M-!+RY+H26@5$(IKD]8$XW9&V0DG(79)9"_;ML4?V:L@\M,BIR9S M*:/P$25B;`_EHC:JA90+<=+26%M>8#"XERD#F7A0]XLB)A<.!EI!+E9C9CXZ"/*+H=G(JT M<'VX9S/G.E=T%B6N67`K%LQ4T81!BP928.HIG"?3A8I3I1*IG^\>>3'A40LT M<*K73S64&VV."E5PRJETW`6 M)51E(EJ6C4:$=UQJZ4.*<@+'$JBR#W)::#H+6ECF)2*$*8J;M'08U$#,*04" M8T.P6]4M`H:M./)KZ8@5&$KI[;PJ.5M>W=3>P7#Q/X@]"';%%4IZZM2Q6LF0 M<+IW3\\>12J",-=BUN656(IV7@ZF%&U-@PWX%I4A])T@8%"%T1^9U466*@IR MS\C!S<65*"LC'%Z:DL^%D).>B/$0KJ"ULK#%,KP10JJ;7FM.#C\$O@3E2]IF M#GIEBL# ML=>UYI@%28MA>KJ@!`')3W4Q%WIN0SBT1>5-5IXRJEX3V,^,R;-;351@F&F4 MX2R:/M\11(DG`^FFXKHI,*)/G?H041'Y>=*5V9DV,<43P[38K$-EXF$&6YB% MDD4!EN)(..>SZ$Z19TMIFTQ$N3/EW*XNKR)ZC:L!TY78X+0WZ/Y,8M08UW`' M*&V]P76VJKV9J&B&)<'4S9)L0HM.:\=)H7$RGP[UT01#)$I1SM9KR&,8$>%5 M-#']]Z*GC+:.%V<@6EW7K5V`6L%D/&2J_^9U5X1=N*.DK;3E(ROSIZ]B`;V+V^^BGR#YI;J!(Y]HK^WCX,AG$%ZX)HL(Y+_'@[]=`K;<6:$U:XI@/R:A33=4 MAYH@]LJXQW3A7)^4':729+)G$>_'..@44@R7',]!8'UF%#(5%LJ75PS8*VA% M?P4F$O>'%'`A@*Q%65XC)EQE3ZDU&H-57A>V+OG7@JUT6B=()A&U?DG5?9K5 M5"K1@>]73F:65SC%5ST";<+%?S7H@$3(?R!5.*%A9C(U@9R3@`%66HPQ&IQU M@E5X-N3U@J:5%SH(A5XH2U\8AG'1A6)8AB-!AF:8AE.EAFSH$VC8AG!X70`P AAW18AW9XAWB8AWJXAWS8AW[XAX`8B((XB(18B'08$``[ ` end -----END PRIVACY-ENHANCED MESSAGE-----